Skip to main content
Equibles
GRDX logo

GRDX · GridAI Technologies Corp. · Metrics

Track GRDX — free

Use GRDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GRDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.42 -0.13 (-2.34%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Aug 21, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern one year from the date these financial statements are issued. ... As a result, the Company concluded that its plans at this stage do not alleviate substantial doubt about the ability to continue as a going concern.”
View the 10-Q filed Aug 21, 2026
Market Cap
$38.65M
Shares
7.13M
Volume · Nov 12 59.82K Avg daily vol (3M) 114.74K

GRDX metrics

60 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.42
Market cap
$38.65M

Price action

23 metrics
Price change (1W)
+2.2%
Price change (30D)
+22.0%
Price change (3M)
+68.7%
Price change (6M)
+60.9%
Price change (YTD)
+19.1%
Price change (1Y)
+48.8%
Trailing year
Price change (5Y)
—
52-week high
$6.80
52-week low
$2.01
Change from 52-week high
-18.4%
Change from 52-week low
+176.8%
Annualized volatility
127.2%
Annualized volatility (3M)
109.2%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.5
RSI (14D)
59.3
Price vs SMA 50
+31.8%
Price vs SMA 200
+54.9%
Avg volume (3M)
116,618
Relative volume
0.8
Average dollar volume
$482,167

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
7.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.7
reciprocal yield 37.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-52.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-1,813.6%
Operating margin
-19,540.0%
Trailing 12 months
Net margin
-17,634.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$22.34M
Net income (TTM)
−$20.61M
Trailing 12 months
Diluted EPS (TTM)
$-5.92
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.90

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-138.6%
Return on assets
-55.7%
Debt / equity
0.1
Current ratio
0.2
EBITDA (TTM)
−$15.57M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$296,640
Latest balance sheet
Cash & equivalents
$1.38M
Total assets
$37.04M
Total debt
$1.68M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.12M
Capital expenditures (TTM)
—
R&D (TTM)
$1.54M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
19
13F filer change QoQ
+5
Institutional ownership
8.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.0%
Private-fund adviser ownership
3.9%
Active holders' share change QoQ
+68.3%
Holder tenure
2.6
Price vs estimated holder cost
+30.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1604191 CUSIP 33749P507 13F (30d) 10 filings 10 filers Visit website Investor relations